SCHEMBL2162108

SCHEMBL2162108

COc1ccc(Cl)cc1C(=O)Nc1sc2c(c1C(=O)O)C(C)OC2

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
ALDH1A1 P00352 6/20 0.46
KCNMA1 Q12791 4/20 0.46
NOD1 Q9Y239 1/20 0.46
HSD17B10 Q99714 3/20 0.45
NPC1 O15118 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163568 0.88 MAPT (0.51) MAPTALDH1A1HSD17B10NPSR1TP53
SCHEMBL2162120 0.85 CNR1 (0.57) MAPTALDH1A1KCNMA1HSD17B10NPC1
SCHEMBL2162084 0.83 ANO1 (0.54) NOD1MEN1KMT2A
SCHEMBL4842211 0.76 MEN1 (0.50) MAPTALDH1A1NOD1NPC1TP53
SCHEMBL2162606 0.73 ANO1 (0.43) MAPTALDH1A1HSD17B10NPSR1TP53
SCHEMBL2163131 0.72 CNR2 (0.40) MAPTALDH1A1NOD1NPC1RAB9A
SCHEMBL2162416 0.70 CNR2 (0.59)
SCHEMBL4138685 0.70 MAPT (0.75) MAPTALDH1A1HSD17B10NPC1TSHR
SCHEMBL24426911 0.70 ANO1 (0.42) MAPTNOD1TP53RAB9ALMNA
SCHEMBL2163111 0.69 CNR2 (0.46) MAPTALDH1A1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US disclosed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, OPRL1 MAPT 1751/4885ALDH1A1 1497/4885KCNMA1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.